Renal impairment as a risk factor for chemotherapy induced neutropenia in the treatment of trifluridine/thymidine phosphorylase inhibitor plus bevacizumab

Related articles

1. Risk factors associated with febrile neutropenia in patients with esophageal cancer receiving 5-fluorouracil plus cisplatin combination chemoradiotherapy

   This article has 6 authors:

   1. Daiki Eto
   2. Ken Shiraiwa
   3. Ryota Tanaka
   4. Takahiro Sumimoto
   5. Ryosuke Tatsuta
   6. Hiroki Itoh

2. Tolerability and Clinical Benefit Assessment of Continuous Roginolisib Administration in Patients with Cancer including Metastatic Uveal Melanoma

   This article has 40 authors:

   1. Michele Maio
   2. Anna Maria Di Giacomo
   3. Matteo Simonelli
   4. Agnese Losurdo
   5. Pavlina Spiliopoulou
   6. Vincenzo D'Alonzo
   7. Giovanni Amato
   8. Monica Valente
   9. Hugo Barcenilla
   10. Anette Johnsson
   11. Laura Gonzalez
   12. Ziyang Tan
   13. Lakshmi Kanth Tadepally
   14. Petter Brodin
   15. Michael Lahn
   16. Giusy Di Conza
   17. Rebeca Zorrilla
   18. Lars van der Veen
   19. Alessio Bevilacqua
   20. Paramjit Kaur
   21. Tracey Hammett
   22. Marco Durini
   23. Andrea Corsi
   24. Nikhil Sindhwani
   25. Mariaelena Occhipinti
   26. Robert Snijder
   27. Ayad Abdul-Ahad
   28. Aniko Meijer
   29. Umberto Postiglione
   30. Gregory Price
   31. Gillian Hopton
   32. Emily Wood
   33. Vincent Vuaroqueaux
   34. Anne-Lise Peille
   35. Jill Graham
   36. Ming Poi
   37. David Spetzler
   38. Carmelo Carlo-Stella
   39. Armando Santoro
   40. Jeff Evans

3. Platinum Selection in Immune Checkpoint Inhibitor-Based Therapy for Recurrent or Metastatic Head and Neck Cancer: A Multi-Institutional Retrospective Study

   This article has 8 authors:

   1. JUMPEI YOSHIDA
   2. NAOKI FUKUDA
   3. TAKUMI ITO
   4. KENJI NAKANO
   5. CHIYOE KITAGAWA
   6. HIROKI MITANI
   7. SHUNJI TAKAHASHI
   8. YUJI MIURA